Comparison · Last verified: April 23, 2026
By The RX Index Editorial Team · Pricing cross-checked against official Mochi and Noom published sources within the last seven days · 11-min read
Mochi vs Noom: Which GLP-1 Program Is Better in 2026?
Bottom line
Mochi Health is the pick if you want predictable monthly billing, included registered-dietitian access, and a simple two-piece price ($79 membership + $99–$199 medication = $178–$278/mo all-in, all doses). Noom Med is the pick if you specifically want behavioral coaching wrapped around your medication, you’re starting on a lower-dose microdose path, or you want help getting brand-name Wegovy, Zepbound, or Ozempic through insurance.
Mochi vs Noom at a glance: the first-screen verdict
If you want predictable monthly billing and the simpler price formula, Mochi wins. If you want behavioral coaching and app structure with your medication, Noom wins. If you specifically want a microdose-first start, Noom’s Microdose GLP-1Rx is built for that. If you want FDA-approved brand-name medication with real insurance support, neither is the strongest fit — that’s Ro.
| What matters most | Pick | Why |
|---|---|---|
| Predictable monthly billing, no quarterly prepay | Mochi Health | Mochi bills monthly. Every Noom GLP-1Rx plan prepays 12 weeks at a time. |
| Simplest, easiest-to-audit price formula | Mochi Health | $79 membership + $99–$199 medication. Same price at every dose. |
| Behavioral coaching, daily lessons, app structure | Noom Med | Decade-plus behavior-change platform with the GLP-1 Companion module. |
| Lower-dose microdose-first GLP-1 path | Noom Med (Microdose) | $79 to start, ~$199/mo equivalent ($597 every 12 weeks). |
| Regular video visits with a board-certified obesity-medicine physician | Mochi Health | Live video visits with board-certified providers and included registered dietitian. |
| Brand-name FDA-approved GLP-1 with insurance + prior-auth help | Ro Body (not Mochi or Noom) | Both can route to brand-name. Ro is the program built deliberately around it. |
| Tirzepatide on a budget | Mochi Health | $278/mo all-in for compounded tirzepatide vs. ~$299/mo on Noom's GLP-1Rx Plus. |
| You're already on Noom and the app keeps you consistent | Stay on Noom | Don't switch on price alone if the program is working for you. |
How much does Mochi cost compared with Noom? Real 2026 numbers
Answer: Mochi’s all-in monthly cost is $178 for compounded semaglutide ($79 membership + $99 medication) or $278 for compounded tirzepatide, billed monthly. Noom Med structures its GLP-1 plans on a 12-week prepay model — Microdose runs about $199/mo equivalent ($597 every 12 weeks), the standard GLP-1Rx plan currently shows $129/mo on Noom’s pricing page but $279/mo in Noom’s cost blog (the actual checkout price needs to be verified), and the Plus tirzepatide tier runs about $299/mo equivalent ($897 every 12 weeks). The Mochi numbers are stable. The Noom standard GLP-1Rx number is a legitimate $1,800/year question depending on which Noom price is real at your checkout.
This is the part competing pages get wrong. They list Noom at “$199/mo” without showing the real cash that hits your card every quarter. They list Mochi at “$39” without showing that’s just the first-month membership promo, not the medication-included total.
Mochi cost — the simple part
Mochi runs a clean two-piece price: a membership fee plus a medication add-on. Both billed every month. No quarterly prepay surprises.
| Mochi plan | Membership | Medication add-on | First month with promo | Ongoing total |
|---|---|---|---|---|
| Compounded semaglutide (all doses) | $79/mo | $99/mo | $39 + $99 = $138 | $178/mo |
| Compounded tirzepatide (all doses) | $79/mo | $199/mo | $39 + $199 = $238 | $278/mo |
| Wellness Plus (with qualifying insurance) + sema | $69/mo | $99/mo | $39 + $99 = $138 | $168/mo |
Multi-month commitment options also exist on Mochi ($199 quarterly, $399 semi-annual, $799 annual membership). Medication is billed separately on top. Verify current rates at checkout. Verified April 23, 2026.
Noom Med cost — the part nobody warns you about
Noom updated its pricing for new accounts effective March 31, 2026. There are five Noom Med program SKUs, and the GLP-1 paths are billed every 12 weeks — not every month.
| Noom Med plan | Start price | Ongoing/mo equivalent | Real cash per period | Medication included? |
|---|---|---|---|---|
| Telehealth (brand-name route) | $69–$149 (varies) | ~$99/mo | Billed quarterly | ❌ No — medication billed separately by insurance/pharmacy |
| Microdose GLP-1Rx | $79 (first 4 weeks) | ~$199/mo | $597 every 12 weeks | ✅ Yes — compounded semaglutide |
| GLP-1Rx (standard) | $129 first period | $129/mo (pricing page) · $279/mo (cost blog) | $387 or $837 per quarter | ✅ Yes |
| GLP-1Rx Plus | $149 first period | ~$299/mo | $897 every 12 weeks | ✅ Yes |
| Weight-Loss Pill (metformin) | $69–$99 first month | $99/mo | Billed quarterly | ✅ Yes — metformin |
⚠ A real warning about Noom’s pricing
Noom’s own published pricing page and Noom’s cost article currently show different ongoing prices for the standard GLP-1Rx plan ($129 vs. $279). We’re not going to pretend we know which one renders at your specific checkout. If your checkout shows $129/mo, Noom is genuinely cheaper than Mochi. If it shows $279, Mochi is cheaper by about $100/mo. Verify before paying.
52-week totals — the actual annual decision
Most “Noom is cheaper” claims fall apart at the first quarterly renewal. Here’s what each path looks like over a full year.
| Path | First period | Renewals | 52-week total (approx.) |
|---|---|---|---|
| Mochi compounded semaglutide | $138 first month with promo | 11 × $178 monthly = $1,958 | ~$2,096 |
| Mochi compounded tirzepatide | $238 first month with promo | 11 × $278 monthly = $3,058 | ~$3,296 |
| Noom Microdose GLP-1Rx | $79 first 4 weeks | 4 × $597 quarterly = $2,388 | ~$2,467 |
| Noom GLP-1Rx (standard) — pricing-page rate | $129 first period | 4 × $387 quarterly = $1,548 | ~$1,677 |
| Noom GLP-1Rx (standard) — cost-blog rate | $129 first period | 4 × $837 quarterly = $3,348 | ~$3,477 |
| Noom GLP-1Rx Plus | $149 first period | 4 × $897 quarterly = $3,588 | ~$3,737 |
| Noom Telehealth (brand-name route) | $69–$149 first month | 4 × $297 quarterly = $1,188 | ~$1,257–$1,337 program fee + medication cost |
Mochi numbers are stable and verifiable. The Noom standard GLP-1Rx number is a legitimate $1,800/year question depending on which Noom price renders at your checkout. This is the single most useful thing to verify before you pay. Verified April 23, 2026.
Mochi = physician + dietitian + video visits. Noom = app-led behavior change + medication support. Same FDA-approved goal, completely different experience.
What do you actually get? The two care models compared
Answer: Mochi pairs you with a board-certified obesity-medicine physician and a registered dietitian for regular video visits, with provider messaging between visits and 24/7 customer support including a real phone line. Noom is app-first — you complete an asynchronous intake, a clinician reviews and prescribes, and most ongoing contact happens through Noom’s lessons, tracking, and care-team messaging inside the app. Mochi feels like a virtual obesity clinic. Noom feels like a clinical app.
What’s included with Mochi
- ✅ Regular video visits with a board-certified provider
- ✅ Registered dietitian access (typically $100+/mo elsewhere)
- ✅ 24/7 customer support + real phone line: +1 (619) 648-1247
- ✅ Provider messaging between visits
- ✅ Medication management and dose adjustments included
- ✅ Patient portal and mobile app
- ✅ HSA/FSA accepted; shipping included in medication prices
- ✅ Optional: lab work via Quest ($99–$149 if uncovered), genetic testing, sleep apnea assessment
- ✅ Wellness Plus tier with qualifying insurance: advanced nutrition therapy, custom diet planning, behavioral therapy, and health screenings
What’s included with Noom Med
- ✅ Full Noom app — daily psychology-based lessons, food and weight tracking, color-coded food system, community
- ✅ GLP-1 Companion module: protein tracking, Muscle Defense workouts, side-effect guides
- ✅ Clinical care from licensed board-certified physicians and nurse practitioners
- ✅ Asynchronous messaging with your care team through the app
- ✅ Welli AI-powered personalization
- ✅ Certificate of Analysis available on request (careteam@noom.com)
- ⚠️ No HSA/FSA card acceptance at checkout — documentation available for reimbursement claim
- ⚠️ Not available in all 50 states
Which medications does each one carry?
Answer: Mochi publicly lists compounded semaglutide ($99/mo all doses), compounded tirzepatide ($199/mo all doses), and brand-name Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Rybelsus, and Trulicity through insurance. Noom Med lists compounded semaglutide (Microdose and standard tiers), compounded tirzepatide (Plus tier), and brand-name Wegovy (pen and pill), Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, and Bydureon through insurance. Neither currently lists Foundayo (orforglipron) — Ro does.
| Medication | Mochi | Noom Med |
|---|---|---|
| Compounded semaglutide injection | ✅ $99/mo, all doses | ✅ ~$199/mo (Microdose) or standard GLP-1Rx |
| Compounded tirzepatide injection | ✅ $199/mo, all doses | ✅ ~$299/mo (GLP-1Rx Plus) |
| Compounded semaglutide alternate formats (oral, sublingual, microdose) | Multiple formats publicly described — verify at intake | Microdose tier only |
| Wegovy® (semaglutide injection) | Listed via insurance | Listed via insurance |
| Wegovy® pill (oral semaglutide) | Listed via insurance | Listed via insurance |
| Ozempic® (semaglutide) | Listed via insurance | Listed via insurance |
| Zepbound® (tirzepatide pen + KwikPen) | Listed via insurance | Listed via insurance |
| Mounjaro® (tirzepatide) | Listed via insurance | Listed via insurance |
| Saxenda® / Victoza® (liraglutide) | Listed | Listed |
| Rybelsus® (oral semaglutide tablet) | Listed | Not in verified materials |
| Bydureon® (exenatide ER) | Not in verified materials | Listed |
| Trulicity® (dulaglutide) | Listed | Listed |
| Foundayo® (orforglipron — FDA-approved April 1, 2026) | Not listed | Not listed |
| Metformin / non-GLP-1 oral options | Listed (also Topamax, Contrave) | Weight-Loss Pill plan, $99/mo |
Required note on compounded medications
Compounded semaglutide and compounded tirzepatide are not FDA-approved. Per FDA, compounded drugs are not reviewed for safety, effectiveness, or quality before being dispensed. Novo Nordisk is the only U.S. company with FDA-approved semaglutide products (Wegovy®, Ozempic®, Rybelsus®). Eli Lilly is the only U.S. company with FDA-approved tirzepatide products (Zepbound®, Mounjaro®). FDA has specifically stated that compounded versions cannot be marketed as the same as, generic versions of, identical to, or clinically proven equivalents to FDA-approved drugs.
A damaging admission, plainly
Neither Mochi nor Noom is the strongest choice if FDA-approved brand-name GLP-1 with insurance support is your priority. Ro Body is the program built deliberately for that path — it carries Foundayo (orforglipron, FDA-approved April 2026), Wegovy pen, Wegovy pill, Ozempic, Zepbound pen, Zepbound KwikPen, and Mounjaro at LillyDirect/NovoCare/TrumpRx-matched pricing, with a dedicated insurance concierge and a free GLP-1 Insurance Coverage Checker.
Check Ro Body eligibility — get started for $39, then as low as $74/month →Pick Mochi vs Noom by your situation: 6 buyer profiles
The right answer depends on your budget, medication preference, whether you want behavioral coaching or clinical care, and whether either provider’s regulatory situation matters to you.
1. “I want predictable monthly billing and the simplest price to audit”
At $178/mo all-in for compounded semaglutide or $278/mo all-in for compounded tirzepatide, billed monthly with no 12-week prepay surprises, Mochi is the easiest program to budget for. Add live video visits with a board-certified obesity-medicine physician and an included registered dietitian, and the value gets stronger.
Check Mochi eligibility →2. “I want behavioral coaching, lessons, and an app that keeps me accountable daily”
Behavior change is what Noom built fifteen years of expertise around. The GLP-1 Companion, daily psychology-based lessons, food-and-weight tracking, and the community structure are the strongest behavioral-change tooling of any GLP-1 program available right now.
See Noom GLP-1Rx plans and confirm your checkout price →3. “I want a lower-dose microdose ramp designed to reduce observable side effects”
Noom Microdose is purpose-built around the gentler ramp. Per Noom’s own published case-study material, the Microdose protocol uses lower starting doses with gradual increases (one published example reached approximately 0.6 mg semaglutide). At $79 to start and roughly $199/mo equivalent ($597 every 12 weeks), it’s also Noom’s most affordable GLP-1 path.
See Noom Microdose →4. “I want FDA-approved brand-name medication through insurance with prior-auth help”
Ro carries Foundayo (FDA-approved April 2026), Wegovy pill, Wegovy pen, Ozempic, Zepbound pen, Zepbound KwikPen, and Mounjaro at LillyDirect/NovoCare/TrumpRx-matched pricing, with a dedicated insurance concierge that handles prior-authorization paperwork.
Check Ro Body eligibility →5. “I want flat-rate compounded with no separate membership fee”
If the two-piece pricing on Mochi and the 12-week prepay on Noom both bother you, Eden runs a single-line price with no separate membership fee. Same price at every dose, multiple format options, in-house 503A pharmacy, available across the U.S.
See Eden’s GLP-1 program →6. “I specifically want compounded oral, sublingual, or needle-free”
If injections are the dealbreaker and you want a compounded oral or sublingual GLP-1 path, SHED is built around that exact intent. Mochi has oral and sublingual options too, but SHED is the specialist.
See SHED’s oral GLP-1 options →Still not sure between Mochi and Noom?
Five questions, one personalized recommendation, no email required.
Get my personalized GLP-1 path →Is Mochi Health legit? What we verified about the lawsuit and the pharmacy
Answer: Yes, Mochi Health is a real, operating, LegitScript-certified telehealth provider available in all 50 states and Washington, D.C., staffed by board-certified obesity-medicine physicians. It is also the named defendant in an active Eli Lilly federal lawsuit (Case No. 3:25-cv-03534, N.D. Cal.) — a federal judge ruled in April 2026 that the case can proceed on California Unfair Competition Law and federal Lanham Act claims after Mochi’s second motion to dismiss was partially denied. None of this means Mochi is unsafe — but a careful buyer should know about it before signing up.
Mochi’s trust signals (what we verified)
- LegitScript certification: confirmed via the LegitScript public registry
- State availability: all 50 states + D.C., confirmed via Mochi’s FAQ
- Clinician credentials: board-certified across family medicine, internal medicine, OB-GYN, bariatric surgery, and pediatrics, with obesity-medicine credentials
- Live phone support: +1 (619) 648-1247, 24/7
- Trustpilot: 4.5/5 across 15,873 reviews — 80% five-star, 9% one-star, Mochi replying to 99% of negative reviews (typically within 48 hours)
Eli Lilly v. Mochi Health Corp. — the real timeline
| Date | Event |
|---|---|
| April 23, 2025 | Eli Lilly filed Case No. 3:25-cv-03534 in the U.S. District Court for the Northern District of California against Mochi Health Corp., Mochi Medical CA P.C., Mochi Medical P.A., and Aequita Pharmacy LLC, alleging California UCL, California FAL, federal Lanham Act, and civil conspiracy violations. |
| August 28, 2025 | Oral argument held on Mochi's motion to dismiss. |
| October 24, 2025 | Court granted the motion to dismiss the original complaint without prejudice, with leave to amend. Most media coverage stopped here — incorrectly treating this as the end of the case. |
| Late 2025–early 2026 | Lilly filed a First Amended Complaint. |
| April 2026 | U.S. District Judge Jacqueline Scott Corley granted in part and denied in part Mochi's motion to dismiss the First Amended Complaint. Lilly is allowed to proceed on the California UCL claim and the federal Lanham Act claim. The civil conspiracy claim was dismissed as not plausibly alleged. |
Aequita Pharmacy — the regulatory action
- March 13, 2025: Washington Pharmacy Quality Assurance Commission issued a Limited Stop Service order against Aequita. Aequita could not compound or dispense compounded products in Washington until the order was resolved.
- September 2025: Washington state issued a discipline notice — Aequita entered an agreed order including restrictions on sterile compounding, monitoring, quarterly reporting, and continuing education. State inspectors had identified deficient practices creating immediate jeopardy to patient safety.
Mochi has publicly denied owning Aequita; Lilly’s amended complaint alleges otherwise, and the ownership question is part of what is now in active litigation. If active federal litigation against your provider is a dealbreaker, Eden is an alternative — Eden was not among the four telehealth companies named in Lilly’s April 2025 lawsuits.
Is Noom Med legit? What we verified about state availability, billing, and refunds
Answer: Yes, Noom is a publicly visible, fifteen-year-old behavior-change company that launched Noom Med in late 2023. It is not currently named in any of the Eli Lilly compounded-GLP-1 lawsuits, partners with compounding pharmacies that provide a Certificate of Analysis on request, and carries a 4.5/5 Trustpilot rating across 66,112 reviews. It is also not available in all 50 states, prepays you 12 weeks at a time on every GLP-1Rx plan, and has documented cancellation friction.
Noom’s trust signals (what we verified)
- Fifteen-year track record as a behavior-change company; Noom Med added late 2023
- Trustpilot: 4.5/5 across 66,112 reviews — 60% five-star, 4% one-star, Noom replying to 100% of negative reviews within 24 hours
- Certificate of Analysis: available on request from careteam@noom.com
- FDA compliance language: posts the required disclaimer on all compounded medication content
- Chief Medical Officer: Dr. Jeffrey Egler, MD — double board-certified in family medicine and lifestyle medicine
⚠ Noom state availability — read this before you sign up
Noom Med is not available in all 50 states for every plan. The Noom Microdose GLP-1Rx Program specifically excludes Alabama, Arkansas, Iowa, Louisiana, and Mississippi due to state regulations on compounded medications. Other Noom Med plans may have additional state restrictions — verify on noom.com/med for your specific state and plan before paying.
Noom billing — the part that catches people
Every Noom GLP-1Rx plan is billed every 12 weeks, not monthly. A “$199/mo” Microdose plan means you pay $597 upfront every quarter. Mid-cycle cancellations are not generally prorated — if you cancel in week 6 you’ve still paid for weeks 7–12. This is the single most common Noom complaint pattern outside of the cancellation flow itself.
See Noom Med plans and confirm your checkout price →Cancellation, refunds, and billing — Mochi vs Noom side-by-side
Answer: Mochi runs two separate subscriptions (a health membership and a medication subscription), and per BBB complaint records, canceling one does not cancel the other. Noom Med refunds may be available unless a prescription has already been written. Plan to cancel both Mochi subscriptions explicitly. Plan to cancel Noom before your renewal date.
| Mochi Health | Noom Med | |
|---|---|---|
| Subscriptions to cancel | Two — health membership and medication subscription | One — your 12-week GLP-1Rx subscription |
| Where you cancel | Patient portal at joinmochi.com or by calling +1 (619) 648-1247 | Noom app settings, subscription portal, or app store (depending on signup path) |
| Refund policy | Prescription medications cannot be returned or refunded; prescription sales are final | Noom Med refunds may be available unless a prescription has already been written; branded-med refunds within 7 days unless a clinical visit has occurred |
| Documented friction pattern | Customers report charges continuing after canceling one of two subscriptions; multi-month plans not prorated | Cancellation flow routes through retention screens with discount offers; some users report difficulty reaching support |
| The single thing to do before canceling | Confirm both subscriptions are canceled and get written confirmation | Check your renewal date and cancel before the next 12-week cycle bills |
Source: Mochi refund policy at joinmochi.com/refunds; Noom’s published refund policy support docs; BBB complaint records for Mochi Health (with Mochi business responses). Verified April 23, 2026.
What real Mochi and Noom users actually say
Answer: Mochi reviewers most often praise the dietitian access, the live physician relationship, the flat all-doses pricing, and the ease of the intake. The most common Mochi complaint is the two-subscription billing structure. Noom reviewers most often praise the app, the daily lessons, the GLP-1 Companion features, and the program structure. The most common Noom complaints are billing and cancellation friction.
On Mochi (Trustpilot, 4.5/5 · 15,873 reviews)
“Easy to navigate. Prompt appointment with providers and ease of ordering medication.”
Trustpilot reviewer. Used as a user-experience signal, not evidence of medical efficacy. No commercial relationship with this reviewer. Most common documented complaint: the two-subscription billing structure — canceling the medication subscription does not cancel the health membership (per BBB business responses).
On Noom (Trustpilot, 4.5/5 · 66,112 reviews)
“I love the Noom app! It’s easy to use…”
Trustpilot reviewer. Used as a user-experience signal, not evidence of medical efficacy. Most common documented complaint: users feeling stuck in the 12-week prepay structure when trying to resolve medication or support issues mid-cycle.
We don’t and won’t imply these results are typical for either provider. Individual experience varies based on plan, state, medication path, and how clearly you understood the billing terms before signing up.
What FDA actually says about compounded GLP-1s
Answer: Per FDA, compounded drugs are not FDA-approved, meaning they have not been reviewed by FDA for safety, effectiveness, or quality before being dispensed. As of July 31, 2025, FDA reported receiving 605 adverse-event reports associated with compounded semaglutide and 545 associated with compounded tirzepatide. FDA has also specifically warned about dosing errors with compounded injectable semaglutide — particularly confusion between milligrams, milliliters, and “units” — some of which have required hospitalization.
Questions to ask before paying for any compounded GLP-1
- Which exact medication is being prescribed (semaglutide, tirzepatide, or another GLP-1)?
- Is it compounded or FDA-approved brand-name?
- Which specific pharmacy will fill it (503A or 503B, named pharmacy, in my state)?
- What is the concentration (mg/mL)?
- Are dosing instructions written in milligrams or units (confusion between them is a documented source of FDA-reported overdoses)?
- What syringe size is provided?
- What happens if the medication is delayed in shipping?
- How do I reach a clinician within 24 hours if I have a side effect?
- What is the refund and return policy after the prescription is written?
This list applies to Mochi, Noom, Eden, SHED, and every other compounded provider. It is not specific to either side of this comparison.
Decision flowchart: Mochi = clinician-led virtual clinic. Noom = app-led behavior change with medication in the background.
Should you switch from Noom to Mochi? The honest 8-step checklist
Answer: Switch from Noom to Mochi only if your actual Noom renewal cost is materially higher than Mochi for the same path, you don’t rely on the Noom app for daily structure, you’ve confirmed Mochi serves your state for your medication, and you’ve timed the switch to your Noom renewal date so you don’t pay for both. If you’re switching only because Noom feels “more expensive” — verify the math first.
- Confirm your current Noom plan name and renewal date. Telehealth ($99/mo equivalent), Microdose ($199/mo equivalent), GLP-1Rx standard ($129–$279/mo equivalent — verify yours), or GLP-1Rx Plus ($299/mo equivalent).
- Confirm whether your current Noom plan includes medication. Telehealth does not. The three GLP-1Rx plans do.
- Compare the apples-to-apples Mochi total. Compounded semaglutide on Mochi = $178/mo all-in. Compounded tirzepatide on Mochi = $278/mo all-in.
- Check Mochi state availability for your medication path. All 50 states + D.C., but verify any state-specific requirements at intake.
- Time the switch to your Noom 12-week renewal date. Canceling mid-cycle means paying for weeks you won’t use. Cleanest move: cancel Noom right after your prescription ships in the current cycle and start Mochi as that cycle ends.
- Confirm Mochi can support your specific dose and formulation. If you’re at a high tirzepatide dose, ask Mochi at intake to confirm.
- Decide whether you’ll miss the Noom app. If the daily lessons and tracking are what’s keeping you on track, switching only on price is a false saving.
- Cancel Noom in writing and get confirmation. Don’t trust a cancel flow without an emailed confirmation.
When neither Mochi nor Noom is the right answer
If you specifically want FDA-approved brand-name GLP-1 with insurance support, flat-rate compounded with no membership fee, or a needle-free oral compounded path, there are better-matched providers than either Mochi or Noom.
| Your situation | Stronger fit | Why |
|---|---|---|
| FDA-approved brand-name with insurance support and prior-auth help | Ro Body | Carries Foundayo (FDA-approved April 2026), Wegovy pen, Wegovy pill, Ozempic, Zepbound pen, Zepbound KwikPen, and Mounjaro at LillyDirect/NovoCare/TrumpRx-matched pricing. Dedicated insurance concierge and free GLP-1 Insurance Coverage Checker. Get started for $39, then as low as $74/month with annual plan. |
| Flat-rate compounded with no separate membership fee | Eden | No membership fee, same price at every dose, in-house 503A pharmacy. Was not among the four telehealth companies named in Lilly’s April 2025 lawsuits. |
| Needle-free compounded oral or sublingual GLP-1 | SHED | Built specifically around the no-injection compounded path. Strong fit for needle-averse patients who want a compounded oral or sublingual semaglutide. |
Mochi vs Noom — frequently asked questions
Is Mochi cheaper than Noom?+
It depends on which Noom plan and which Noom price renders at your checkout. Mochi compounded semaglutide is $178/mo all-in, billed monthly. Noom's standard GLP-1Rx plan currently shows $129/mo on Noom's pricing page and $279/mo in Noom's cost article — verify yours. Mochi compounded tirzepatide ($278/mo) is consistently cheaper than Noom GLP-1Rx Plus ($299/mo) on the published pricing.
Does Noom Med include the medication in the price?+
It depends on the plan. The three GLP-1Rx plans (Microdose, standard, and Plus) include compounded medication in the per-period price. The Telehealth plan ($99/mo after the first month) does not — that program fee covers clinical access only, and the medication itself is billed separately by your insurance or pharmacy.
Does Mochi include the medication in the membership?+
No. Mochi runs a two-piece price: a $79 membership plus a separate medication add-on ($99/mo for compounded semaglutide, $199/mo for compounded tirzepatide). Both are billed monthly. Your total all-in is $178 or $278 per month.
Which is better for behavior change, Mochi or Noom?+
Noom. Behavior change is the entire reason Noom exists as a company. Daily psychology-based lessons, food and weight tracking, Welli AI personalization, the GLP-1 Companion module, and Muscle Defense workouts are built into the Noom app and included with every Noom Med plan.
Which is better for clinician access, Mochi or Noom?+
Mochi. Regular video visits with a board-certified obesity-medicine provider plus included registered dietitian consultations are Mochi's core differentiator. Noom's clinician contact is largely asynchronous through the app.
Is Noom Med available in all 50 states?+
No. Per Noom, Noom Med is not available in all 50 states. The Microdose GLP-1Rx Program specifically excludes Alabama, Arkansas, Iowa, Louisiana, and Mississippi. Some other Noom Med plans have additional restrictions. Verify on noom.com/med for your specific state and plan before paying.
Is Mochi Health available in all 50 states?+
Yes — all 50 states plus Washington, D.C. Mochi also offers a pediatric weight-management program, which most competing providers do not.
Is the Eli Lilly lawsuit a reason to stay away from Mochi?+
It's a reason to know what you're signing up for. As of April 2026, the case (Eli Lilly v. Mochi Health Corp. et al., Case No. 3:25-cv-03534) is allowed to proceed in the U.S. District Court for the Northern District of California on California Unfair Competition Law and federal Lanham Act claims after Mochi's second motion to dismiss was partially denied. Mochi continues to operate, fill prescriptions, and provide care in all 50 states. If you're not comfortable with active litigation against your provider, Eden is a reasonable alternative — Eden was not among the four telehealth companies named in Lilly's April 2025 lawsuits.
Can I cancel Mochi or Noom whenever I want?+
Yes, both allow cancellation at any time. The friction is in how. Mochi requires you to cancel both subscriptions (membership and medication) separately — canceling one does not cancel the other. Noom requires you to cancel through the app, subscription portal, or app store depending on how you signed up, and refunds are not generally available once a prescription has been written or a clinical visit has occurred.
Can I use HSA or FSA for Mochi or Noom?+
Mochi accepts HSA/FSA cards directly per Mochi's FAQ. Noom states it does not directly accept HSA/FSA as a payment method, but Noom Med may qualify under many HSA/FSA plans and Noom can provide documentation for reimbursement. Reimbursement is not guaranteed — confirm with your plan administrator.
What's the difference between Noom Weight and Noom Med?+
Noom Weight is the original Noom app — behavior change, lessons, and tracking only, no medication, around $17–$70/month depending on plan length. Noom Med is the prescription program that adds clinical care and access to GLP-1 or other weight-loss medications, and runs $69–$299+/month depending on the path you choose.
Does Mochi prescribe Foundayo (orforglipron)?+
Foundayo is a brand-new oral GLP-1 from Eli Lilly that received FDA approval on April 1, 2026. As of this page's verification date, neither Mochi nor Noom publicly lists Foundayo. Ro publicly says Foundayo is available on Ro at LillyDirect-matched pricing with insurance support.
Is Noom Med legit?+
Yes. Noom is a fifteen-year-old behavior-change company that launched Noom Med in late 2023. It is not currently named in any of the Eli Lilly compounded-GLP-1 lawsuits, partners with compounding pharmacies that provide a Certificate of Analysis on request, posts the required FDA disclaimer on compounded medications, and carries a 4.5/5 Trustpilot rating across 66,112 reviews.
Is Mochi Health legit?+
Yes — Mochi Health is a real, operating, LegitScript-certified telehealth provider available in all 50 states and D.C., staffed by board-certified obesity-medicine physicians, with a 4.5/5 Trustpilot rating across 15,873+ reviews. It is also the named defendant in an active Eli Lilly federal lawsuit (Case No. 3:25-cv-03534, N.D. Cal.) — a federal judge ruled in April 2026 that the case can proceed after Mochi's second motion to dismiss was partially denied. Both things are true.
How we built and verified this Mochi vs Noom comparison
This page was built by reviewing each provider’s public pricing pages, support and refund documentation, the federal court docket for the Eli Lilly v. Mochi Health case, the Washington Pharmacy Quality Assurance Commission’s actions against Aequita Pharmacy, FDA guidance on compounded GLP-1 medications, and current Trustpilot snapshots for both providers. Last verified: April 23, 2026.
| Verified item | Source |
|---|---|
| Mochi membership and medication pricing | joinmochi.com and joinmochi.com/faqs |
| Mochi refund policy | joinmochi.com/refunds |
| Noom Med pricing | noom.com/med/pricing, noom.com/med/glp1-microdose, and Noom's cost blog |
| Noom refund policy | Noom's published support docs |
| Eli Lilly v. Mochi Health Corp. et al. (Case No. 3:25-cv-03534) | U.S. District Court Northern District of California docket and orders |
| Aequita Pharmacy regulatory action | Washington Pharmacy Quality Assurance Commission public records (March 2025 Limited Stop Service; September 2025 discipline notice) |
| FDA guidance on compounded GLP-1s | FDA's pages on compounded GLP-1 medications and adverse-event statistics through July 31, 2025 |
| Foundayo (orforglipron) FDA approval date | FDA press announcement, April 1, 2026 |
| Trustpilot profiles | Trustpilot snapshots for joinmochi.com and noom.com |
| Mochi complaint pattern | BBB profile for Mochi Health (complaint patterns and business responses) |
If you spot something out of date, email corrections to editorial@therxindex.com.
The verdict, one more time
Choose Mochi Health if…
You want predictable monthly billing, the simpler price formula, included dietitian access, and you’re comfortable with Mochi’s current legal and regulatory situation.
Check Mochi eligibility and current pricing →Choose Noom Med if…
You want behavioral coaching and the Noom app tightly integrated with your medication, you’re comfortable with 12-week prepay billing, and you specifically want the Microdose path or the brand-name Telehealth route. Confirm your checkout price before committing — the standard GLP-1Rx plan currently renders at two different prices on Noom’s own surfaces.
See Noom Med plans and confirm your checkout price →Still not sure which GLP-1 program is right for you?
Five questions · One personalized recommendation · No email required
Start the quiz →Sources
- Mochi Health — FAQ, pricing, and membership
- Mochi Health — refund policy
- Noom Med — pricing page
- Noom Med — GLP-1 Microdose program
- U.S. District Court Northern District of California — Eli Lilly v. Mochi Health Corp. et al., Case No. 3:25-cv-03534
- Washington Pharmacy Quality Assurance Commission — public records on Aequita Pharmacy (March 2025 Limited Stop Service; September 2025 discipline notice)
- FDA — guidance on compounded GLP-1 medications and adverse-event statistics through July 31, 2025
- FDA — Foundayo (orforglipron) approval press announcement, April 1, 2026
- Trustpilot — joinmochi.com (4.5/5 · 15,873 reviews) and noom.com (4.5/5 · 66,112 reviews)
Medical disclaimer: This page is for informational purposes only and does not constitute medical advice. FDA-approved GLP-1 medications carry medication-specific warnings — always consult a licensed healthcare provider before starting any prescription medication. Compounded medications are not FDA-approved and have not been reviewed by FDA for safety, effectiveness, or quality.
Affiliate disclosure: This page contains affiliate links. The RX Index may earn a commission if you sign up through links on this page. Our methodology is published — this does not influence our recommendations.
Last verified: April 23, 2026 · By The RX Index Editorial Team